STOCK TITAN

Galmed Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Business Update on Thursday May 13

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

TEL AVIV, Israel, May 6, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will host a conference call and webcast on Thursday, May 13, 2021, to provide an update on current developments with respect to its clinical programs for Aramchol™ and to discuss financial results for the quarter ended March 31, 2021.  

Galmed Pharmaceuticals Logo

Conference Call & Webcast:

Thursday May 13, 2021, 8:30 AM ET

Toll Free:                                 1-877-425-9470
Toll/International:                   1-201-389-0878
Israel Toll Free:                       1 809 406 247
Conference ID:                       13719139  
Webcast:                                 http://public.viavid.com/index.php?id=144593

Replay Dial-In Numbers

Toll Free:                                 1-844-512-2921
Toll/International:                   1-412-317-6671
Replay Pin Number:                13719139
Replay Start:                           Thursday May 13, 2021, 11:30 AM ET
Replay Expiry:                        Thursday May 27, 2021, 11:59 PM ET

About Aramchol and Non-alcoholic Steatohepatitis (NASH)

Aramchol (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism. Aramchol's ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating downregulation of the three key pathologies of NASH: steatosis, inflammation and fibrosis. The effect of Aramchol on fibrosis is mediated by downregulation of steatosis and directly on human collagen producing cells. Aramchol has been granted Fast Track designation status by the FDA for the treatment of NASH.

NASH is an emerging world crisis impacting an estimated 3% to 5% of the U.S. population and an estimated 2% to 4% globally. It is the fastest growing cause of liver cancer and liver transplant in the U.S. due to the rise in obesity. NASH is the progressive form of non-alcoholic fatty liver disease that can lead to cardiovascular disease, cirrhosis and liver-related mortality.

About Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study. We are also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide and recently initiated a first in human study.

Cision View original content:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-report-first-quarter-2021-financial-results-and-provide-business-update-on-thursday-may-13-301285427.html

SOURCE Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd

NASDAQ:GLMD

GLMD Rankings

GLMD Latest News

GLMD Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
Israel
16 Zeev Tyomkin St 4th Fl

About GLMD

galmed pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or fabacs. aramchol is initially being developed for treating non-alcoholic steato-hepatitis, or nash, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. galmed pharmaceuticals galmed’s business has been, in its current legal structure, was incorporated in israel on july 31, 2013 as a privately held company. however, operating since 2000 under a different group of companies established in the same year. galmed was co-founded by professor tuvia gilat and allen baharaff, based on professor gilat’s extensive research in fabac’s and nash.